2012 – Page 23 – Retraction Watch

Another retraction for potential prostate cancer test from Hopkins

Earlier this year, we reported on the case of Robert Getzenberg of Johns Hopkins, who retracted a 2007 paper in Urology that was “at the center of two 2009 lawsuits brought by a company that funded the work.”

Getzenberg has now retracted a related paper, “Analysis of a serum test for prostate cancer that detects a second epitope of EPCA-2,” published in The Prostate in 2009 and cited nine times, according to Thomson Scientific’s Web of Knowledge.

The notice in The Prostate goes further than the one in Urology, using the word “falsification:” Continue reading Another retraction for potential prostate cancer test from Hopkins

Amarin pulls a Romney: For the second time in a week, premature news of FDA drug approval posted, then retracted

There is apparently a special this week on websites posting news of drug approvals before they actually happen.

On Monday, USA Today inadvertently posted a story about the approval of Qsymia, a weight loss drug, several hours before the FDA made an announcement. Today, Amarin, which makes a compound designed to lower triglycerides, put up a site saying that the drug had been approved by the FDA. Trouble was, that decision isn’t expected until July 26. According to Reuters: Continue reading Amarin pulls a Romney: For the second time in a week, premature news of FDA drug approval posted, then retracted

Closing loop, Science retracts Hill group oxo paper

Last month, we broke the news that Emory chemist Craig Hill and colleagues were retracting two papers in the Journal of the American Chemical Society and one in Science. At the time, the Science move was pending, but now the journal has officially pulled the article, titled “A Late-Transition Metal Oxo Complex: K7Na9[O=PtIV(H2O)L2], L = [PW9O34]9–”.

The notice reads: Continue reading Closing loop, Science retracts Hill group oxo paper

Two retractions in biophysics journal, one because article is “too preliminary and potentially misleading”

We’ve seen vigorous debates here on Retraction Watch about when studies should be retracted. Does it require fraud? Just not being reproducible? Somewhere in between?

Given the apparent divergence of opinions on the issue, we thought it would be worth highlighting a case that involves language we haven’t seen before. Here’s the notice for “Apoptosis of CT26 colorectal cancer cells induced by Clostridium difficile toxin A stimulates potent anti-tumor immunity,” which originally appeared online in Biochemical and Biophysical Research Communications in April: Continue reading Two retractions in biophysics journal, one because article is “too preliminary and potentially misleading”

Hmmm: SAGE’s attorney explains why weight loss retraction notices said less than those of other journals

In May, we broke the story of Edward Shang, a weight loss surgeon who made up most, if not all, of the patients he reported on in at least one study. We’ve been following the case since then, including three more retractions in the Journal of Parenteral and Enteral Nutrition (JPEN).

As we noted in a June 22 post, the notices in JPEN were a bit more lean than the first notice we found, in Surgery for Obesity and Related Diseases. The latter read: Continue reading Hmmm: SAGE’s attorney explains why weight loss retraction notices said less than those of other journals

Another retraction for grad student who specializes in plagiarism and forging co-authors’ names

We have an update on the case of Moêz Smiri, a graduate student working in a Tunisian-French laboratory, whose bold method of bulking up his CV proved a bit trop ambitieux.

As we reported back in August 2011, Smiri had plagiarized repeatedly from previously-published work, and forged the names of co-authors, in a 2010 article in Plant Science on the effects of cadmium on peas. That article was one of at least six papers on which Smiri appeared as first author — a pretty impressive output for a young researcher.

Among the list was article in Ecotoxicology and Environmental Safety, “Effect of cadmium on resumption of respiration in cotyledons of germinating pea seeds.” That paper is now retracted. According to the notice: Continue reading Another retraction for grad student who specializes in plagiarism and forging co-authors’ names

USA Today posts story on approval of diet drug too soon, takes it down

USA Today has yanked back a story about a diet drug’s approval by the FDA — because the FDA hasn’t actually approved the drug yet.

The FDA is scheduled to announce its decision on the subject of the story — Vivus’ Qnexa — today. The decision has been closely watched.

The story, headlined “New diet drug helps heavy patients lose 10% of weight,” includes a lot of reporting, including comments from the president of Vivus about a change in name from Qnexa to something else. (We’ll leave USA Today that apparent scoop, although others might not.) It was posted on the Salem, Oregon’s Statesman Journal at 12:16 p.m. today, presumably Eastern, since it was taken down before the West Coast arrived at 2 p.m. Continue reading USA Today posts story on approval of diet drug too soon, takes it down

Three papers by German management prof retracted for duplication, statistical issues

Ulrich Lichtenthaler, a management professor in Germany, has had three papers retracted by two different journals, after readers noticed statistical irregularities.